MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.11 USD
-0.07 (-2.20%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $3.13 +0.02 (0.64%) 7:34 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Brokerage Reports
MEI Pharma, Inc. [MEIP]
Reports for Purchase
Showing records 41 - 60 ( 141 total )
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 7th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 7th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Fiscal Q1 EPS: Awaiting Presentation of Pracinostat Data at ASH and Clinical Strategy Update, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Fiscal 2015 Results, Expecting Pracinostat Update at ASH, Reiterate NEUTRAL Rating
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Updated Pracinostat Data in Frontline Elderly AML Patients-Responses Continue to Improve, Waiting on Overall Survival
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Continued Positive Signs in AML - Sufficient for Pracinostat''s Future?
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 8th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 25th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Fiscal 3Q15 Earnings; Awaiting AML Data in June to Determine Path Forward
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 4th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Downgrading to NEUTRAL and Reducing Price Target to $3; Pracinostat Misses Endpoint in MDS, Difficult Path Forward
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Is Pracinostat''s Future in Question? Downgrade to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 23rd
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L